All In Biotech

Drug Trial Radar · NCT03166215

Study of TAK-935 as an Adjunctive Therapy in Participants With Developmental and/or Epileptic Encephalopathies

A Phase 1b/2a Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Escalation Study With an Open-Label Part to Examine the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-935 as an Adjunctive Therapy in Subjects With Developmental and/or Epileptic Encephalopathies

Last checked: Nov 20, 2026Latest source record: Sep 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

18

Actual

Start

Aug 17, 2017

Primary completion

Sep 19, 2018

Study completion Sep 19, 2018

Sponsor

Lead sponsor
TakedaTakeda (TAK)
Sponsor type
Industry
Collaborators
Healx AI
First posted
May 25, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to characterize the multiple-dose safety and tolerability profile of TAK-935 in adult participants with developmental and/or epileptic encephalopathies.

Conditions

  • Developmental and/or Epileptic Encephalopathies

Interventions

  • TAK-935Drug

    TAK-935 tablets.

  • PlaceboDrug

    TAK-935 placebo-matching tablets.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With at Least One Treatment-Emergent Adverse Event (TEAE), as Reported by the Participants or Participant's Caregivers or Observed by the Investigator, After TAK-935 TreatmentTime frame: From first dose up to 30 days post last dose (approximately up to 120 days)

Locations

11 sites in 1 country. Site status is shown where the registry gives one.

  • Xenoscience

    Phoenix, Arizona

  • Medsol Clinical Research Center

    Port Charlotte, Florida

  • University of South Florida

    Tampa, Florida

  • Center for Integrative Rare Disease Research

    Atlanta, Georgia

  • Bluegrass Epilepsy Research

    Lexington, Kentucky

  • Mid-Atlantic Epilepsy and Sleep Center

    Bethesda, Maryland

  • The Comprehensive Epilepsy Care Center for Children and Adults

    St Louis, Missouri

  • Northeast Regional Epilepsy Group

    Hackensack, New Jersey

  • Thomas Jefferson University

    Philadelphia, Pennsylvania

  • Medical University of South Carolina

    Charleston, South Carolina

  • University of Virginia Health Sciences Center

    Charlottesville, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.